CVRx Business Summary

CVRx, Inc. (CVRX) is a commercial-stage medical device company that generates revenue primarily through the direct sale of its proprietary Barostim system, an implantable neuromodulation therapy, to hospitals and cardiac centers. The company’s business is concentrated in the Heart Failure (HF) segment, specifically targeting patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy. As of early 2026, CVRx has transitioned to a high-growth phase following the January 1, 2026, implementation of Category I CPT codes, which standardized physician reimbursement and reduced prior authorization friction. The company operates primarily in the United States, which accounts for over 90% of its $56.7 million in 2025 revenue, while maintaining a secondary commercial presence in Europe. CVRx competes with medical technology firms such as Impulse Dynamics, Medtronic, Boston Scientific, and JenaValve Technology; however, it maintains a unique market position as the provider of the first and only FDA-approved therapy designed to trigger the body’s natural baroreflex to restore autonomic balance. CVRx was founded in 2001 by Dr. Robert Kieval, a veteran medtech entrepreneur who previously held leadership roles at Medtronic. The current executive team is led by President and CEO Kevin Hykes, who took the helm in February 2024 bringing over 30 years of experience from companies including Augmedics, Bardy Diagnostics, and Medtronic. Other key leaders include CFO Jared Oasheim, Chief Medical Officer Dr. Philip B. Adamson (formerly of Abbott), and Chief Operating Officer Brent Binkowski. The company’s leadership is further bolstered by a board of directors featuring industry heavyweights such as Kevin Ballinger, former Executive Vice President at Boston Scientific, and Mitch Hill, former CFO of Inari Medical. CVRx has historically been backed by premier healthcare investors including New Enterprise Associates (NEA), Johnson & Johnson Innovation (JJDC), and SightLine Partners, and maintains a strategic debt facility with Innovatus Capital Partners to fund its ongoing BENEFIT-HF pivotal trial.